REG - Brookfield Pvt.Cap. Hikma Pharmaceutical - Statement regarding Hikma Pharmaceuticals Plc

Hikma PharmaceuticalsAnnouncement

04/02/2026 17:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260204:nRSD7720Ra&default-theme=true

RNS Number : 7720R  Brookfield Private Capital (DIFC)Ld  04 February 2026

 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE
OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A
VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.

 

THIS IS AN ANNOUNCEMENT FALLING UNDER RULE 2.8 OF THE UK CITY CODE ON
TAKEOVERS AND MERGERS (THE "CODE").

 

 

FOR IMMEDIATE RELEASE

 

4 February 2026

 

Statement regarding Hikma Pharmaceuticals Plc ("Hikma")

 

Brookfield Private Capital (DIFC) Limited, acting for and on behalf of funds
managed and/or advised by its affiliates ("Brookfield") notes the recent press
speculation and confirms that it does not intend to make an offer for Hikma.

 

This announcement is made by Brookfield in accordance with Rule 2.8 of the
Code. As a result of this announcement Brookfield (and any person acting in
concert with it) will, except with the consent of the UK Panel on Takeovers
and Mergers (the "Panel"), be bound by the restrictions contained in Rule 2.8
of the Code.

 

Under Note 2 on Rule 2.8 of the Code, Brookfield reserves the right to set
aside the restrictions in Rule 2.8 in the following circumstances: (i) with
the agreement of the board of Hikma; (ii) if a third party announces a firm
intention to make an offer for Hikma; (iii) if Hikma announces a Rule 9 waiver
proposal (see Note 1 of the Notes on Dispensations from Rule 9) or a reverse
takeover (as defined in the Code); or (iv) if there has been a material change
of circumstances (as determined by the Panel).

 

Enquiries:

 

Brookfield

Marie Fuller
 
+44 (0) 20 4557 4334

 

Important information

 

This announcement is not intended to, and does not, constitute, represent or
form part of any offer, invitation or solicitation of an offer to purchase,
otherwise acquire, subscribe for, sell or otherwise dispose of any securities
or the solicitation of any vote or approval in any jurisdiction whether
pursuant to this announcement or otherwise.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  STRDZLFBQLLLBBZ



            Copyright 2019 Regulatory News Service, all rights reserved